Newsletters
South Korea has developed the world’s first recombinant protein-based anthrax vaccine, reported to have fewer side effects.
According to Yonhap News Agency, the vaccine named "Barythrax," developed by the Korea Disease Control and Prevention Agency (KDCA), was approved by the Ministry of Food and Drug Safety in April.
Unlike other vaccines, the newly developed recombinant protein-based anthrax vaccine uses only a small portion of the disease-causing microbe to stimulate the immune system, rather than the entire pathogen.
This approach eliminates the risk of exposure to the toxins produced by the anthrax bacteria, resulting in fewer side effects.
Kim Gab-jung, Director General of the Disease Diagnosis and Analysis Department at KDCA, stated that the new vaccine will make a significant contribution to public health.
There have been no reported cases of anthrax in South Korea since the year 2000.
1 min read
5 min read
